![Free-eBooks.net](/resources/img/logo-nfe.png)
![All New Design](/resources/img/allnew.png)
A Market Research Report on
10 Ways in which
Current Macro
Upheavals in China
will Impact Global
Life Sciences
Industry
What would this Report Cover?
10 Macro Upheavals in China Impacting Global Healthcare
Unabated European
The highlights and
Strengthening global
Integrating countries
Focusing on
pharma investment in
lowlights faced by Chinese
health through
through commercial
regulatory reforms
China
vaccine developers
R&D
partnerships
Increasing commitments
Accelerating Industrial
Consolidation within the
Export and Sales of Medical
Promoting the
to health assistance and
Transformation and
service provider
Devices and Consumables
Internationalization of the
cooperation
Talent Development
space
across Nations Globally
Pharmaceutical Industry
2
Macro Upheavals Impacting Global Healthcare (1/5) The Highlights and
Unabated European
Lowlights Faced by
Pharma Investment in
Chinese Vaccine
China
Developers
▪ Big Pharma players are investing in China-specific projects and
▪ An intriguing microcosm of the status of development of the entire growing their footprint across the mainland as China represents an business can be seen in the highs and lows encountered by ever-increasing share of their global profits Chinese vaccine developers in their quest to deploy a COVID-19
vaccine
▪ In order to more effectively and comprehensively connect with Chinese medication developers, Boehringer Ingelheim (BI) built a
▪ While Chinese companies were among the first in the world to new hub in Shanghai to consolidate its R&D, and business introduce vaccine candidates into the clinic, validating the development operations in China
advancements made by the country's overall biopharmaceutical industry and significantly raising the stature of Chinese scientific
▪ Additionally, Novo Nordisk unveiled ambitious intentions to research abroad, it was ultimately a Big Pharma-backed vaccine combine their Chinese and international businesses with an from Pfizer and German biopharma player BioNTech that first emphasis on clinical development
crossed the finish line
▪ Novo Nordisk’s "China Essentials" program seeks to simultaneously
▪ Chinese-developed COVID-19 vaccines received approval for submit clinical trial applications for new drugs in China and routine or emergency use in China and several other nations, other countries for the first time, with a goal of 90 percent by 2025
including the UAE, Egypt, and Brazil, but not by the US or the EU, which were regarded as the world's two most stringent regulatory bodies
3
Macro Upheavals Impacting Global Healthcare (2/5) Integrating Countries
Strengthening Global
through Commercial
Health through R&D
Partnerships
▪ China’s 14th Five-Year Plan calls for an average annual increase
▪ Chinese and British agencies convene as part of a bilateral Global in R&D spending across the industry of more than 10%; in Health Dialogue that determines areas of shared interest for addition to the requirements for the innovative development of the potential future cooperation
pharmaceutical industry in the fundamental principles, these requirements are also reflected in terms of development goals
▪ Chinese government is assisting the Africa Centres for Disease Control and Prevention (CDC) and has also inked MOUs with
▪ By 2025, the share of newly sold innovative items in the increase the WHO and numerous bilateral partners to address some in operating revenue for the entire industry will further rise healthcare constraints
▪ The National Natural Science Foundation of China (NSFC) and the
▪ Private health sector businesses, organizations engaged in health China Grand Challenges project were established to promote research, and other entities are being engaged by China and scientific and technical innovation that may address important foreign partners
issues facing emerging nations
▪ This might entail setting up a platform for cooperation in global
▪ The initiative has supported research on AIDS vaccine health and technical professionals and should develop a mutual development, child and maternal mortality, tuberculosis (TB) understanding as a foundation for more productive collaboration treatments, vaccines, and more at prestigious universities, research centers, and hospitals in China
4
Macro Upheavals Impacting Global Healthcare (3/5) Increasing Commitments
Focusing on Regulatory
to Health Assistance and
Reforms
Cooperation
▪ China is collaborating with international partners to remove
▪ China is promoting global health by covering the agreements for obstacles that prevent more high-quality and reasonably priced working with African nations, like FOCAC for health cooperation Chinese healthcare products from entering the global market, which could have a larger impact on world health
▪ Under FOCAC, a forum for China-Africa health development has been established, and agreements have been made to offer health
▪ To provide technical support and support reforms that bring aid to African nations
Chinese regulations and standards in clinical trials, drug approval, and manufacturing into line with international norms, WHO and the
▪ As part of efforts to boost international cooperation, the National Medical Products Administration which is China's main Chinese government has signed MOUs with several multilateral regulatory agency for drugs and medical devices have come organizations, most notably the WHO for global health together
▪ China is actively developing better health policies, demonstrating
▪ Chinese businesses can more easily pursue concurrent domestic its commitment to playing a greater role in global health, and certification and WHO prequalification of their products beginning to demonstrate the thematic goals, kinds of cooperation, and levels of engagement that the government envisions 5
Macro Upheavals Impacting Global Healthcare (4/5) Accelerating Industrial
Consolidation within the
Transformation and
Service Provider
Talent Development
Space
▪ The development of the pharmaceutical industry in China depends
▪ The biopharma boom in China has also energized the CRO and on encouraging technical collaboration in the pharmaceutical CDMO space, with demand greatly outstripping supply across many area between business, academia, research facilities, and fundamental services, through acquisitions, Chinese pharmaceutical hospitals, as well as on maximizing the potential of those working in businesses are expanding their market share and entering the that sector globally
global pharmaceutical outsourcing sector
▪ In order to improve collaboration with scientific research
▪ In order to increase its CDMO capability and market reach in institutions and jointly create a national strategic scientific force in Europe, WuXi AppTec made an agreement with Bristol Myers the field of biomedicine, the 14th Five-Year Plan emphasizes its Squibb to purchase the latter's production plant in Couvet, support for innovative pharmaceutical firms Switzerland in 2021
▪ Additionally, the strategy calls for funding the establishment of
▪ To improve its CMC capabilities in the UK and China, Pharmaron independent pharmaceutical R&D organizations, assisting in the purchased a commercial API production plant from Recipharm in creation of premier clinical research facilities, and enhancing the the beginning of 2022
capabilities of clinical research design and research services
▪ These transactions represent a grown Chinese CRO and CMO
market, which grew at a CAGR of 30.8% from 2016 to 2021, much faster than the global average of 9.5%.
6
Macro Upheavals Impacting Global Healthcare (5/5) Export and Sales of
Promoting the
Medical Devices and
Internationalization of the
Consumables across
Pharmaceutical Industry
Nations Globally
▪ In numerous healthcare sub-sectors, China is the second-largest
▪ In terms of going worldwide, China is promoting to support healthcare market in the world, offers the potential to global businesses in synchronizing the registration of novel exporters
medications in China and abroad as well as conducting international multi-center clinical research for developed nations
▪ The most active and vitally essential segment of the Chinese healthcare market for international enterprises continues to be
▪ The globalization of China's pharmaceutical business includes the medical equipment
process of internationalization that also involves the exit of native pharmaceutical firms and the admission of foreign
▪ Medical equipment with advanced technology is typically imported, pharmaceutical firms
while low to mid-range market segments are dominated by native products
▪ This is carried out by actively enticing multinational corporations to establish R&D centers and innovative drug
▪ China's medical device industry is anticipated to grow at a CAGR of manufacturing bases in China, as well as by using cooperative 6.2% from 2020 to 2025, bringing about USD38.4 billion by 2025
development and technology licensing to realize the entry of foreign pharmaceutical companies, in order to drive the development of the
▪ The diagnostics, imaging, and consumables subsectors of the domestic pharmaceutical industry companies Chinese medical device industry accounted for about 50% of the market's value
7
Who should buy this report?
HealthTech
MedTech
Pharmaceutical
Digital Health
Healthcare
Companies
Players
Players
Entities
Providers
Topics of Upcoming Reports
10 Ways in which Technology is Driving Better Efficiency in Clinical Trials
Digital Therapeutics Regulatory Process, Updates and Trends Cost of this report:
Will the Expiry of Humira Market Exclusivity and Entry of its Biosimilars Move the Needle in BioPharma Market?
$2,500
From the Fringes to the Forefront: mRNA is here to Transform Global Health
Annual Subscription:
Melting the Iron Triangle: 10 Healthcare Players aiming Beyond Health Equality to Conquer Health Equity $125,000 $60,000
Robotics: Embarking a New Era in Surgical Innovations (Includes a total of 50 reports) Metaverse: Paving the way for Health 4.0
Healthcare Future Outlook 2023
Patient Engagement- a New Standpoint on Care that is Patient-Centered
E-Rx, the Digital Version of Prescription Improvising the Chances of Better Patient Outcomes
Methodology & Scope
Research Methodology
▪
Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions
▪
We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources
▪
For forecasting, the following parameters are considered:
❑
Market drivers and restraints along with their current and expected impacts
❑
Technological scenario and expected developments
❑
End use industry trends and dynamics
❑
Trends in the consumer behavior
❑
Regulatory scenario and expected developments
❑
Current capacity and expected capacity additions up to 2030
▪
We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate
▪
We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions
▪
All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪
Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn) 11
A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Analysis Methodology
Our Analysis Methodology involves three critical stages: Market Data Analysis
Interpretation &
Data Collection
& Statistical Model
Presentation
Analysis &
Market Trends
Interpretation
Secondary
Research
Market Sizing &
Insights
Analysis
Primary
Research
Data Triangulation &
Presentation &
Validation
Reporting
12
A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Data Triangulation & Data Validation Top Down Approach
Final
Final Market size break up to
Market
rest of segmentation
Size
Validation from
Arriving at market size
Primary Interview
of each segment
Summarization of revenue
generated from companies
Validation from
to arrive at total market size
Primary Interview
Revenue generated by products & Final
services offered by companies
Summary
Bottom Up Approach
13
A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Key Benefits for Stakeholders from this Report Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors 14
A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Time Frame
Report Attribute
Details
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn) Base Year for
2021
Estimation
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Report Coverage
Company Profiles, Competitive Landscape, Regulatory Landscape, Future Opportunities Report Customization (5 working days) with purchase. We will provide you with data that is Customized Report
currently not a part of our scope as a part of 2022-Forecast
customization
2030
Period
Pricing and purchase
Avail customized purchase options to meet options
your exact research needs
What kind of Data is Presented
in this Report?
This report presents data, which is: Reliable
Expert-verified
Real
Comprehensive
Easy to read
The report is prepared
The data is prepared by
Allowing you to
Covers everything you
You do not have to be a
using a proven
a team of highly qualified
confidently make
would need to know
market expert to
methodology and
& experienced research
smarter business
about the market
understand what really is
insightful research
analysts & vetted by our
and strategic
including market size,
happening on the market
local associates
decisions
competitive analysis &
and how it works
much more
www.insights10.com
About
Lifesciences Market
Research Reports you
can trust
A large database of over 30,000 syndicated market research reports in pharmaceuticals and healthcare sector at global, regional as well as country level. We also provide customized research reports tailor made to suit your needs
Get Insights to take
informed Business
Decisions
Insights10 is a healthcare focused market research firm founded with an aim of being an insights driven company in the data driven world and delivering actionable insights that can drive decision and strategy making process for businesses
Market Research Reports
across various domains of healthcare Pharmaceuticals
Digital
Medical
Healthcare
OTC &
Clinical
(Diseases & Drugs) Health
Devices
Services
Nutraceuticals
Trials
Market Research Reports
1
6
Full-Time Engagement
Customized Reports
2
7
Conference Coverage
Our
Primary Research
3
Services
8
Competitive Intelligence
Strategic Research Projects
4
9
Regulatory Compliance
Database Services
5
10
Report Subscription Services
Our Research Process
01
02
03
04
05
Identification of
Market
Collection of
Collaboration
Verification &
Data
Dynamics
Data
of Data
Analysis
Statistical Databases
Company Websites/Annual Reports
Data
Sources
Trade Publications
We have access to multiple highly
Online Databases
reliable free and subscription data
sources. We have many years of
experience to understand which
Published Research Reports
sources are more dependable for what and which to prefer for the reliable and Whitepapers
latest information.
Press Releases of Key Market Players
Over the years, we have developed an in-depth experience of executing market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions
Research Projects Done
Project Leadership Team
Dr. Purav Gandhi
Mukesh Nayak
Ritu Baliya
Atharva Bahad
Founder & CEO
Head - Marketing
Engagement Manager
Consultant
Purav is a physician and an
Mukesh is an engineering graduate
Ritu has over 6 years of experience in Atharva is a B.Tech (Biotechnology) and entrepreneur with 12+ years of
with an MBA in Marketing. He is a
strategy building, market assessments, MBA in Hospital and Health Management experience in Healthcare & Life
seasoned healthcare market
market sizing, and RWE for global MNC
with 2 years of experience working in Sciences industry spanning across
research & marketing professional healthcare & biopharma clients across consulting and project management in strategy, market access, health
with a progressive experience of over diff. markets (America, Europe, Africa, healthcare and Non-Government
informatics and RWE, digital health, 20 years in Life Sciences, Pharma
APAC and Middle East). Her areas of
organizations. Conducted
analytics and data science. Purav
and Medical Device sectors. With an
expertise include: Indentifying emerging comprehensive research and market
studied medicine from Gujarat
in-depth understanding of primary
trends in life sciences industry,
sizing exercise to understand the
University and also completed his MBA research, he has conducted
Competitor landscape assessment,
business potential for modern digital from IIM-Kozhikode. Purav started his hundreds of interviews of various
Disease opportunity assessments etc.
trends. Conducted comprehensive
career with Deloitte working on strategy stakeholders in pharma & healthcare She is a pro in secondary and primary secondary research for the subjects
consulting engagements and also co-
& completed several research
research with a deep domain expertise including the UK Mobility Aids market, founded ConvergeHealth by Deloitte.
projects across life sciences industry.
in healthcare sector.
Brazil’s Ophthalmology market, etc.
7 years of experience working with leading organizations in pharma, MedTech and healthcare domain. Some of our recent clients are mentioned below
… and many more
We would be happy to help.
Web: www.insights10.com
Email: insights@insights10.com Call: (+91) 931 639 7935
Whatsapp: (+91) 931 639 7935